INTRODUCTION
Stable gastric pentadecapeptide BPC 157 is a novel anti-ulcer peptide, used in trials for the treatment of ulcerative colitis and now multiple sclerosis, lethal dose (dosage required to kill 1% of the test population, LD1) not reported. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] We recently reviewed its significance [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] as a likely mediator of the Robert's stomach cytoprotection/adaptive cytoprotection [14] [15] [16] [17] [18] [19] and organoprotection, 20, 21 as well as a novel mediator of the Selye's stress coping response, [22] [23] [24] [25] generally known, but still not completely clarified.
Briefly, to support the pleiotropic beneficial effects of BPC 157 application, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] we will review the particular background of these essential holistic concepts, the Robert's stomach cytoprotection [14] [15] [16] [17] [18] [19] and organoprotection 20, 21 and the Selye's stress coping response (Fig. 1 ).
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Background of the Robert's concept (stomach cytoprotection and organoprotection) versus the Selye's concept (stress coping response)
Robert's stomach cytoprotection [14] [15] [16] [17] [18] [19] and organoprotection 20, 21 and the Selye's stress coping response [22] [23] [24] [25] both intend to reestablish homeostasis. In the late 1970's the concept of Robert's cytoprotective homeostasis (cell protection) was related to the stomach, [14] [15] [16] [17] [18] [19] but soon it was further extended (i.e., as a principle acting in the stomach mucosa integrity maintenance much like in the maintaining of the other epithelia integrity, stomach cytoprotection → organoprotection). 20, 21 Much earlier, Selye's concept was born outside of the gastrointestinal tract, in the adrenal gland, and Selye conceptualized the general syndrome of adaptation (i.e., adrenal gland hypertrophy, thymolymphatic involution, and stomach stress ulcers) to achieve general homeostasis in the whole body while the derangement could explain the genesis of many stress-induced diseases.
Hartmann's discovery of the cortin for the Selye's concept
Of note, Selye's concept was preceded by Hartmann's discovery of cortin. 26, 27 Cortin was extract from the adrenal gland cortex, and called life-maintaining factor. 26, 27 It kept adrenalectomized animals alive, and was essential for the treatment of Addison disease patients. 26, 27 On the one hand, these outbreaks 26, 27 initiated the search for and discovery of corticosteroids by Kendal and Reichstein groups. 28, 29 On the other hand, this lead Selye to propose the concept that the most essential role of the "adrenotropic" principle in the coping response was to reestablish homeostasis 22 while two other principles, "thyrotropic" and "histaminergic," remained less emphasized. 22 
Homeostasis
In principle, these concepts [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] consider "homeostasis," (cytoprotection/adaptive cytoprotection, organoprotection) as the organ's protection from injury as well as organ's recovery after injury, as the most important result. The beneficial effects (endogenous and exogenous) of the agent supposed to mimic the Fig. 1 . BPC 157 has beneficial effects and thus leads to stomach cytoprotection → organoprotection of the whole gastrointestinal tract, including both prophylactic and therapeutic effects for pre-existing lesions in individuals with the most complex disturbances, such as internal and external fistulas, or anastomosis complicated with severe colitis (indicated as +1). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] In addition, there is a particular effect on endothelial integrity (indicated as +2).
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Together, these may result in the particular activation of blood vessels during injury, vessel occlusion, or organ perforation, the recruitment of the vessel to organize an adequate shunting and bypass occlusion (indicated as=3). 101, 113, 117, 118 Furthermore, the effect of BPC 157 is due to its interaction with and modulation of the NO system, and its interaction with prostaglandin, dopamine, and serotonin systems has also been documented. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] BPC 157 also acts as a free radical scavenger, counteracts free radical-induced lesions, and normalizes NO and MDA levels in tissues and during ischemia and reperfusion. 101, 113, 114, [116] [117] [118] Subsequent studies from other groups 2,96-101 have confirmed our original findings. [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] Pleotropic effects involving distinctive receptors, including VEGFR2 and growth hormone receptors, distinctive pathways, including VEGFR2-AKT-eNOS, ERK ½, FAK-paxillin, FoxO3a, p-AKT, pmTOR and p-GSK-3β, and distinctive loops, including stimulation of the egr-1 gene and its corepressor gene naB2, and counteraction of increases in pro-inflammatory and procachectic cytokines, 2, [96] [97] [98] [99] [100] [101] likely minimize the inherent lack of full understanding of the mechanisms that may be involved. However, more important is the practical evidence from a considerable number of the studies, particularly in gastrointestinal research, that intragastric administration or per os administration in drinking water, is equally effective as injections of the supplement administered to rodents, which has been performed in the majority of studies on BPC 157. 12, 41, 43, 48, 51, 54, 55, 58, 59, [61] [62] [63] [82] [83] [84] [85] 89, [91] [92] [93] 98, 114, 116, 117, [143] [144] [145] [146] [147] [149] [150] [151] [152] [153] [154] [155] In reality, in particular along with its safety profile, LD-1 is not achieved, and there are no reported adverse effects in clinical trials; [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] this evidence suggests the ease of practical clinical application. PGs, prostaglandins; NO, nitric oxide; VEGF, vascular endothelial growth factor; VEGFR2, VEGF receptor 2; eNOS, endothelial nitric oxide synthase; FAK, focal adhesion kinase; FoxO3a, transcription factor; p-AKT, phospho-AKT; p-mTOR, phospho mammalian target of rapamycin; p-GSK-3β, phos pho glycogen synthase kinase 3β; MDA, malondialdehyde; GI, gastrointestinal. activity of the supposed mediator (i.e., prostaglandins, corticosteroids) should link theory and practice. The achieved beneficial effects should be the practical realization of the theoretical point of homeostasis (cytoprotection/adaptive cytoprotection, organoprotection) in the body's maintenance of integrity. 4 Unfortunately, the general but insurmountable problem is that neither of the supposed mediators when applied as a therapy could realize in practice the full theoretical assumption that "homeostasis" could be achieved. 4 Inadequate standard mediators activity to homeostasis in Robert's stomach cytoprotection and organoprotection and the Selye's stress coping response
In general, the inadequate functioning of the highly sophisticated theory in real practice is due to considerable limitation in these mediators activity.
Robert's stomach cytoprotection and organoprotection
As emphasized, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] the beneficial effect of prostaglandins as the concept of cytoprotection only works when they are given before injury, but not when given after injury. [14] [15] [16] [17] [18] [19] Likewise, commonly thought to have essential wound healing potential, 30 the standard peptidergic growth factors for the "wound healing concept" confront with an alike problem in practical realization of the high theoretical potential. 1 The angiogenic growth factors for healing in the gastrointestinal tract, and particularly for the healing of the extra-gastrointestinal tissues (i.e., skin, tendon, ligament, muscle, and bone), regularly need special and various delivery systems and various carrier addition. 1 This obstacle obscures the inherent beneficial effect of any peptide 1 (making uncertain whether the peptide, or the carrier or the peptide+carrier(s) complex might be essential for the gotten effect). 1 Selye's stress coping response
The application of the Selye's stress coping response concept 22 to resolving the practical problem of arthritis, 31 resulted in the corticosteroid clinical outbreak. 32 However, the first integrative factor in Selye's stress adaptive response of the body, which could have a large range of beneficial effects that could be accordingly applied as the therapy, remains largely undiscovered. 4 The consequence is the evident gap between the theory (reestablished homeostasis, integrative beneficial effects) and the practical realization (limited beneficial activity of the given agent with the harmful effect as well). This missing point illustrates the misleading evidence that the foreseen integrative mediator that integrates the adaptive bodily response to stress became an argument used in favor of corticotro pin releasing factor (CRF). [33] [34] [35] [36] Namely, CRF has a mild ulcerogenic effect when given centrally. 37 25 that integrative mediator that integrates the adaptive bodily response to stress, remains obscured in the highly sophisticated latter Selye's stress concept presentation. 25 A point of disillusionment appeared in early 1980's with the notion that Selye's concept should be replaced with humbler but more precise ideas. 39 An increase in hypothalamo-pituitary adrenal activity is seen as having adaptive endocrine effects and behavioral consequences via its influence on memory and arousal; and economy of the body from the way peptides play different function depending upon their localization in the body.
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Link between Robert's concept and Selye's stress coping response concept Thereby, taking these general caveats into account, an interesting link between Robert's concept [14] [15] [16] [17] [18] [19] [20] [21] 17 corresponds to Selye's small stress that protects against severe stress (general adaptation). 40 Robert's stomach cell protection (cytoprotection) [14] [15] [16] [17] [18] [19] extended to other organs (i.e., liver, pancreas) (organoprotection) 20, 21 appears as Selye's reestablished homeostasis 22 (as an organoprotective stress coping response that should eliminate damage in any organ (organoprotection), readily reproduced by such agents application). 22 Robert's nonspecific necrotizing agents (strong alcohol, strong base, hypertonic solution, boiled water, given intragastrically; nonsteroidal anti-inflammatory drugs [NSAIDs] and prednisolone given systemically), severe necrotizing stomach lesions and perforating intestinal lesions [14] [15] [16] [17] [18] [19] corresponded to the Selye's diverse nocuous agents given systemically and left the organism severely damaged. 4 Thus, as we already emphasized, 4 it follows that these two concepts have very close interconnections, and thereby, both merit common solution.
Significance of the pleotropic beneficial effects for Robert's concept (stomach cytoprotection/adaptative cytoprotection → organoprotection) and Selye's stress coping response concept
Of note, Robert's concept (stomach cytoprotection/adaptative cytoprotection → organoprotection) on which more focus is put on may be more workable. However, "homeostasis" (i.e., in the stomach as stomach cytoprotection/adaptative cytoprotection, and in the other organs as organoprotection) still warrants eventual realization in more advanced practice (providing that prostaglandins analogues have no more than marginal application in gastroduodenal lesions therapy).
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The antecedent Selye's organoprotective issue, "the damage" consequent to acute nonspecific nocuous agents that produce "the organism severely damaged" in rat experiments, 22 since the very beginning, clearly indicated what should be the essential proof of concept and interposed agent activity supposed to be involved in the counteractive coping response organization. Evidently, the antecedent cortin was the prototype with its activity (and its huge range of beneficial effects). 26, 27 Thereby, this proof has to be a pleotropic beneficial effect as the end result of the application of agents that were supposed to have the essential integrative role of the Selye's (still putative) mediator that integrates the adaptive bodily response to stress 22, 25 whatever particular mechanism lies behind it. 22, 25 Likewise, the resolving of the Robert's stomach cytoprotection/adaptative cytoprotection concept and its extension to the other organs lesions (cell protection that should be generalized) would occur by application of the suited agents capable to achieve such large range of the beneficial effect (stomach cytoprotection → organoprotection=Selye's homeostasis). At the same time, this contention realized (demonstrable pleotropic beneficial effects with the given agent) could mean the practical realization of the theory and accommodations of the previous Selye's original stress concept 22 and subsidiary concepts, braingut concepts, brain peptides, angiogenic growth factors activities. 4 This contention brings us to the elaborate again the significance of the pleotropic beneficial effects of the BPC 157 application along with elaboration of the original Robert's cytoprotection/adaptive cytoprotection/organoprotection concept.
Original Robert's cytoprotection/adaptive cytoprotection/ organoprotection concept
Elaboration with the BPC 157 versus elaboration with prostaglandins, somatostatin, sulfhydryls Original Robert's cytoprotection/adaptive cytoprotection/ organoprotection concept elaborated with standard cytoprotective agents/mediators, prostaglandins, somatostatin, sulfhydryls Direct instillation into the stomach of various highly damaging agents (i.e., absolute ethanol) or application of NSAIDs as the initial background The Robert's cytoprotection/adaptive cytoprotection/organoprotection concept as the wound-healing concept Concept of cytoprotection holds stomach cell protection in order to maintain stomach integrity against various noxious agents (Robert's killing cell by contact) -induced by direct instillation into the stomach of various highly damaging agents (i.e., absolute ethanol), or application of NSAIDs. [14] [15] [16] [17] [18] [19] The next extension of the concept means the generalization of the stomach cell protection to the innate cell protection in the other organs (stomach cytoprotection → organoprotection). 20, 21 Thus, in subsequent order, generalization from stomach epithelia to other epithelia appears, i.e., skin, liver, pancreas, heart, etc., and thereby, the wound-healing concept (providing that the stomach ulcer is much like the skin ulcer a wound that from the unknown reason fail to heal), leading to the axiomatic statement "the healing is always the same." 30 Less emphasized, but essentially important is the final point in the original cytoprotection concept, the continuous presentation of the cytoprotective agent in gastric mucosa, and likely in the gastric juice, and thereby, permanently maintaining stomach mucosa integrity. [14] [15] [16] [17] [18] [19] This however, directly holds that cytoprotective agent would be effective prophylactically (given before injury able to protect stomach mucosa) as well as therapeutically (given after injury, with the pre-existing lesion, able to rescue stomach mucosa). 11 This is however not the case with standard agents (i.e., prostaglandins, somatostatin, sulfhydryls); they are effective only when given before injury, and thereby, less likely to play the role of the endogenous cytoprotective agent in permanent maintenance of the stomach and gastrointestinal tract integrity.
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Original Robert's cytoprotection/adaptive cytoprotection/ organoprotection concept elaborated with BPC 157 as prototype of cytoprotective agents/mediators Pleotropic beneficial activity Unlike the standard agents (i.e., prostaglandins, somatostatin, sulfhydryls) (in)activity, 11 the stable gastric pentadecapeptide BPC 157 actually satisfies these full activity criteria completely.
Essentially stable and native in human gastric juice, BPC 157 is highly effective prophylactically and therapeutically in counter-acting various lesions in the whole gastrointestinal tract. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] This effectiveness accordingly includes distinctive ways of administration, acutely and chronically (i.e., bolus application intraperitoneal, intravenous, intragastric, enema, local bath, and continuous application in drinking water; local gel or cream). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] An interesting point is the local cream application in wound studies (local cream application heals deep skin burns much like stress gastric lesions in mice). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] As a real mediator of the Robert's cytoprotection, in addition to the stomach and gastrointestinal lesions, it has a pleotropic beneficial activity, and counteracts also the lesions in the other organs, liver, pancreas, lung, hearth and brain. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Of particular notation in BPC 157 studies is that each organ lesion counteraction includes different noxious procedures but regularly the same dose regimen which enables to combine the beneficial effects consistently obtained. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Illustratively, beneficial activity in heart assay includes counteraction of the doxorubicin cardiomyopathy, 41 distinctive arrhythmias induced by digitalis, 42 hyperkalemia, 43 hypokalemia, 44 succinylcholine, 45 bupivacaine, 46 and neuroleptics. 47 Pleotropic beneficial activity based on the opposing relationship with alcohol and NSAIDs adverse effects In general cytoprotective/adaptive cytoprotection/organoprotection terms, and pleotropic range of the beneficial activities of BPC 157, and its opposing relationship with the alcohol and NSAIDs adverse effects, already reviewed, 8, 11 this extension is quite logical. The major argument is that the Robert's standard noxious agents, alcohol and NSAIDs, used as the prototype noxious agents in the initial demonstration of the cytoprotection lesions in the stomach, have pleotropic damaging activity. 8, 11 Alcohol and NSAIDs would also regularly induce various lesions in the other organs as well. 11 Vice versa, it is likely that if cytoprotective agents induce the innate counteraction of the initial Robert-lesions (alcohol, NSAIDs) in the stomach, the same agent exhibits an alike counteraction of the other lesions regularly induced by alcohol and NSAIDs (i.e., in liver, brain).
As we reported, this special combined point that should characterize the effects of any suited cytoprotective agent in practice fulfils the corresponding range of beneficial effect of BPC 157.
We noted the antagonization of the corresponding alcoholinduced [48] [49] [50] [51] [52] and NSAIDs-induced 53-57 stomach lesions, much like the counteraction of the liver and brain lesions, which were induced by alcohol [58] [59] [60] or NSAIDs. [53] [54] [55] [56] [57] 61 To emphasize, much like the prototypic acute alcohol-stomach lesion, [48] [49] [50] [51] the beneficial range of the BPC 157 counteracts alcohol in both acute intoxication (protracted drowsiness, increased alcohol level in blood, hypothermia) and chronic intoxication (withdrawal convulsions). 59, 60 Likewise, it counteracts consequences of the chronic abuse (drinking alcohol for 3 months) 58 such as chronic gastric lesions 51 or liver lesions with portal hypertension. 58 For NSAIDsadverse effects (i.e., gastrointestinal, liver and brain injuries), BPC 157 counteraction includes both COX-1 and COX-2 blockers. [52] [53] [54] [55] [56] [57] 61 BPC 157 reduces bleeding after amputation, and may also counteract aspirin induced prolongation of bleeding and thrombocytopenia. 62, 63 An interesting point is that BPC 157 may also prevent and reverse adjuvant arthritis in rats. 64 Thus, unlike mentioned standard agents, BPC 157 achieves stomach cytoprotection → organoprotection.
An important point is that this innate stability (as mentioned, resistant to degradation in human gastric juice more than 24 hours) provides the advantage of the administration using various routes of applications. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] BPC 157 with the stomach cytoprotection concept → wound healing concept
In addition, the other point considers the stomach cytoprotection concept → wound healing concept.
1 Note, the original cytoprotective agenda (with the generalized cell protection, within the same "cytoprotective" background) includes the improved healing in different tissues. 20 grossly, biomechanically and microscopically means demonstration of the both external and internal fistulas healing [82] [83] [84] [85] [86] [87] and consequently, the realization of the simultaneous healing of different tissues. Likewise, is the demonstration of the improved anastomoses healing, 57, [88] [89] [90] [91] [92] gastrointestinal (i.e., esophagogastric, esophagojejunal ileoileal, jejunoileal, colon anastomoses), 57, [88] [89] [90] [91] [92] but also nerve (sciatic nerve) 93 and vascular (abdominal aorta). 94 Consequently, the evidence that it may close and heal the various fistulas [82] [83] [84] [85] [86] [87] and improve anastomosis healing, 57,88-94 may be a proof of the fulfilled wound healing concept.
BPC 157 stomach cytoprotection concept → wound healing concept with respect to angiogenesis and distinction from the standard angiogenic growth factors
The other generalization of the stomach cytoprotection concept → wound healing concept is the application of standard peptidergic growth factors (providing that they are mediators of healing) in both gastrointestinal tract healing (i.e., ulceration healing) and skin wound and soft tissue injuries (i.e., muscle, tendon, ligament, bone healing). 1, 30 In particular, this is due to the effect on the angiogenesis as a common healing point. 30 Third, BPC 157 exerts its effect within the same dose range in healing of the lesions in the whole gastrointestinal tract, as well as the healing of the skin wound, the healing of the severely injured (including transection) muscle, tendon, ligament, and finally bone healing (including pseudoarthrosis healing).
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Contrarily, the standard angiogenic growth factors have limited effect in gastrointestinal tract, and their effect could be different from one part to another. 1 Especially, for the skin wound, muscle, tendon, ligament and bone healing they obviously need various carriers in addition, and thereby, they could exert mostly a local effect. 1 Besides, standard angiogenic growth factors need a different carrier addition, and together may have uncertain activity attribution (peptide; carrier; peptide+carrier complex). 1 Unlike this common negative point for the standard agents application, BPC 157 always given alone, acts alone, and therefore, all of the effects could be clearly described to its own peptide activity. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] In addition, the important point is that BPC 157 may induce also nerve healing, peripherally 93 and centrally. 104 Such clear distinction in angiogenesis is essential (and thereby, "controlling of angiogenesis") 1 and regular with BPC 157. 1 In particular, this should be emphasized since alike distinction is unusual for the standard growth factors, 1 and thereby (angiogenesis/healing/tumor promoting), the fear of tumor promoting known with standard growth factors. Contrarily, "controlling of angiogenesis" is along with an increased angiogenesis to promote healing, 73 an increased expression of vascular endothelial growth factor (VEGF) and subsequent pathways, 2,96-101 and as study of Kang et al., 2 documented, BPC 157 fully counteracted tumor cachexia, and prolonged survival, counteracted increase of the pro-cachectic and pro-inflammatory cytokines, and related molecular pathways effects. 2 In addition, a study showing that BPC 157 actually counteracted tumor promoting effect of VEGF should be also mentioned. 105 This point was already elaborated especially in our shortbowel syndrome study. 91 In rats which underwent large resection of the small bowel, BPC 157 leads to the balanced adaptation of all three intestinal wall layers, resulting in normal weigh achievement, and attenuation of the remote organs damages (i.e., liver and brain), unlike rapidly presented and progressed shortbowel syndrome.
57,91
The concept of cytoprotection as the injury of the stomach endothelium that would precede and induce stomach epithelia damage and BPC 157 "stomach endothelium protection" to the protection of the endothelium of other vessels
The next essential point of the concept of cytoprotection is the injury of stomach endothelium that would precede and induce the stomach epithelia damage, and thereby stomach endothelium protection to protect stomach epithelia as an innate effect of the cytoprotective agents. [106] [107] [108] [109] While the originally noted endothelium protection remains quite strictly confined to the stomach endothelium protection, 106-109 a point we described, is that this means generalization of the "stomach endothelium protection" to the protection of the endothelium of other vessels. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Thus, with BPC 157 use in the resolving of the cytoprotection concept, its local in the stomach to its systemic concept terms, this combined effect could envisage its controlling of endothelium maintenance (as before the stomach cell protection) to be suited for an alike therapy generalization. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] This point was illustrated by the evidence obtained in rats in which abdominal aorta anastomosis (and thereby arterial thrombosis), 94 or inferior caval vein occlusion (and thereby venous thrombosis), 101 or amputation and anticoagulants application (and thereby prolonged bleeding and thrombocytopenias) 63, 64 were present.
Specifically, in rats, with the anastomosed abdominal aorta, thrombosis was either prevented, or once established, reversed. 94 In rats, with the ligation of the inferior caval vein, direct vein injury and thrombosis were counteracted (occlusion up to the right ovarian vein leading to vessel injury, stasis, thrombosis and hemodynamic changes a recapitulation of Virchow). 101 In rats with tail or foot amputation, and heparin, warfarin and aspirin application, without 62 or with nitric oxide (NO)-agents, NO synthase (NOS)-blocker N-nitro-L-arginine methyl ester (L-NAME) or NOS-substrate L-arginine, 63 prolonged bleeding and thrombocytopenia were counteracted. 62, 63 Likewise, in rats with inferior caval vein-ligation thrombocytopenia and prolonged bleeding were all counteracted. 101 Finally, a general argumentation within the commonly accepted concepts, holds that the wound healing process accomplished all of the four major events (vascular constriction, loose platelet plug, fibrin mesh to ensure stability of platelet plug, dissolution of the clot) that occur in a set order following the loss of vascular integrity. 62 Thereby, an agent implemented in wound healing, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] such as stable gastric pentadecapeptide BPC 157, has shown to be effective in wound healing but also effective in bleeding disorders.
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Stable gastric pentadecapeptide BPC 157-NO-systemrelation
For effective application of the background of BPC 157, of particular significance should be BPC 157 interaction with NOsystem. This interaction seems to be always present, while the relevance could be high knowing general importance of NOsystem, and providing a clear demonstration of the interaction between BPC 157 and the whole NO-system in various models and species. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The data so far presented suggested that BPC 157 may modulate NO-system effect, providing that its effectiveness could override the effects of NOS-blockade (induced by NOS-blocker L-NAME), NOS-overstimulation (induced by NOSsubstrate L-arginine application), or NOS-system immobilization (induced by simultaneous administration of L-NAME and Larginine). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The point of homeostasis that may be induced by BPC 157 was shown using the example of L-NAME hypertension, and L-arginine-hypotension, both counteracted with BPC 157 application (while BPC 157 has no influence on normal blood pressure). 49 More specifically, stable gastric pentadecapeptide BPC 157-NO-system-relation could suggest its close participation in Moncada's (maintained vascular integrity, platelets control) homeostatic healing response of NO-system to injury. 7 Seen from the viewpoint of the BPC 157-NO-system-relation, it is important that BPC 157's particular healing effect also affects all events after the loss of vascular integrity. 7 Dependent on circumstances, it reduces either thrombosis (abdominal aorta anastomosis; inferior caval vein occlusion 101 ) or bleeding/thrombocytopenia (amputation; 62, 63 heparin, warfarin, aspirin; 62, 63 after prolonged period of inferior caval vein occlusion 101 ). Furthermore, in a series of different injurious models, acute and chronic, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] BPC 157 consistently promotes healing after severe injuries in various tissues which are spontaneously unable to heal; 1-13 stimulates egr-1 and naB2 genes and different pathways; 96-101 exhibits high safety (LD1 not achieved). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Thus, a hypothesis is that BPC 157 (since it is formed constitutively in the gastric mucosa, stable in human gastric juice, along with significance of NO-synthase and the basal formation of NO in stomach mucosa, greater than that seen in other tissues) exhibits a general, effective competition to both L-arginine analogues (i.e., L-NAME) and L-arginine. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Furthermore, this has some physiologic importance (i.e., controlled NO-generation, providing that in the stomach BPC 157 induced NO-released opposed L-arginine-induced NO-release, and that BPC 157 induced NOreleased is completely resistant to L-NAME application unlike Larginine). 49 It practically supports its beneficial effects illustrating BPC 157 and NO-system mutual (with L-NAME/L-arginine; alone and together) relations. The next concluding arguments are the subset of the evidence obtained in gastric mucosa and mucosal protection, following alcohol lesions, in cytoprotection course, NO-generation, and blood pressure regulation. 49 Furthermore, the evidence includes NSAIDs gastrointestinal, liver, and brain lesions, failed anastomosis, and intestinal adaptation against deterioration after intestine resection. 57, [96] [97] [98] [99] Alcohol acute/chronic intoxication, and withdrawal combined together, may be particular illustration 59, 60 much like the antagonization of thiopental anesthetic effect. 110 Cardiovascular disturbances, chronic heart failure, pulmonary hypertension, and arrhythmias appear as a particular point of counteraction, much like the disturbances after hypokalemia and hyperkalemia, [41] [42] [43] [44] [45] and potassium-cell membrane dysfunction or complex muscle disorders produced by potassium [43] [44] [45] or magnesium overload, 111 or pupil paralysis with atropine. 112 Finally, the BPC 157-NOsystem-relation includes complex healing failure, proved by the fistulas healing, 82, [84] [85] [86] or particular anastomoses healing 88 or vessel occlusion 101, 113 or cytostatic agents application (i.e., doxorubicin, cyclophosphamide). 41, 114 The notation that BPC 157-NOsystem-relation interferes with the effects of neuroleptics merits further elaboration. 115, 116 Finally, BPC 157 application lead to normalization of NO-level in tissues as well as counteraction of free-radicals formation. 113, 114, 116 Of note, how this advantage of modulating NO-system (i.e., particular effect on eNOS gene), may be a practical background which could be further translated into an enhanced clinical performance.
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BPC 157 may have a particular additional effect during the injury on the blood vessel activity: vessel recruitment to circumvent the vessel occlusion
The final argumentation goes to the findings that BPC 157 may have a particular additional effect during the injury on the blood vessel activity, much like vessel recruitment to circumvent the vessel occlusion, presenting an additional shunting and rapid bypassing loops to rapidly reestablish blood flow integrity. 101, 113, 117, 118 The particular illustration to damage counteraction appears with the ischemic/reperfusion colitis, 113 and rapid bypassing loop through arcade vessels. 113 Consequently, circumventing blockades, blood flow was restored, and pale areas without mucosal folds did not occur. 113 Similar evidence follows the ligation of the superior anterior pancreaticoduodenal vein and duodenal congestion lesions, which were completely counteracted by BPC 157 application, both with intraabdominal bath or intragastric application with rapid presentation of the bypassing pathway through inferior anterior pancreaticoduodenal vein to superior mesenteric vein. 117 This corresponds to the general evidence that BPC 157 was used in ulcerative colitis trial and duodenal lesions counteraction. Robert's stomach cytoprotection concept as the peripheral part of the brain-gut axis as beneficial background for the BPC 157 application in various CNS-disorders
Besides, as we reviewed, 5 long ago, the Robert's stomach cytoprotection concept was considered as the peripheral part of the brain-gut axis. 119 The most prominent action of many peptides (i.e., bombesin, thyrotropin-releasing hormone, CRF, neurotensin) on gastric lesions [120] [121] [122] [123] [124] [125] [126] [127] [128] which appears when applied within the specific hypothalamic and brain stem sites or into the cerebrospinal fluid, 128 requires a corresponding effect from periphery.
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And thereby, the beneficial background for the BPC 157 application in various central nervous system (CNS)-disorders holds the commonly accepted knowledge that brain-gut interaction involves, among others, gut-brain axis and interaction, peptidergic growth factors which are native in gastrointestinal tract and have strong antiulcer potency and thus could from periphery beneficially affect CNS-disorders. 5 Initially, corresponding beneficial central influence on serotonin system was seen when BPC 157 was given peripherally and a serotonin release in particular brain areas, mostly nigrostriatal, was changed and markedly increased, 129 Porsolt's test and chronic stress induced immobility reduced more than after imipramine administration while serotonin syndrome (irreversible monoamine oxidase [MAO]-inhibition+serotonin precursor as serotonin substrate) was fully counteracted. 130, 131 Influence on dopamine system goes with the counteraction of the adverse effects of the amphetamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine (MPTP; Parkinson's model in mice), reserpine, haloperidol and other dopamine antagonists. 38, 115, 116, 131, 132 Thus, BPC 157 does not act as a serotonin substrate. 129 BPC 157 does inhibit MAO-inhibition, 131 modulates serotonergic and dopaminergic systems, 38, 115, 116, [129] [130] [131] [132] [133] [134] [135] [136] beneficially affects various behavioral disturbances that otherwise appeared due to specifically (over)stimulated/damaged neurotransmitters systems.
Dopamine system as an additional background for Robert's stomach cytoprotection. BPC 157 modulates dopamine system activity This assumption follows the evidence that the dopamine system provides an additional background also for Robert's stomach cytoprotection 13, [137] [138] [139] [140] [141] and gastric lesions appear after dopamine antagonists, MPTP, and reserpine. 132, 133, 135 Thus, for BPC 157 application as a cytoprotective agent, we could likely envisage an analogy with the counteraction of the stomach lesion induced by NSAIDs much like the counteraction of all others adverse of NSAIDs effects, including the central disturbances. 8 Accordingly, BPC 157 may, in addition to gastric lesions induced by dopamine antagonists, MPTP, and reserpine, counteract also their central disturbances such as akinesia, catalepsy as well as prolonged QTc intervals or sphincter malfunction in periphery. 38, 115, 116, [129] [130] [131] [132] [133] [134] [135] Thus, it may be that BPC 157 does modulate dopamine system activity. A supporting point for such particular modulatory effect is the evidence that BPC 157 counteracts also amphetamine both acute and chronic toxicity. 38, 115, 116, [129] [130] [131] [132] [133] [134] [135] BPC 157 neuroprotective effects
In addition, BPC 157 has neuroprotective effects. It protects somatosensory neurons in capsaicin-treated rats. 53 Sciatic nerve regeneration appears after transection with BPC 157 application, local (into the tube), intragastric or intraperitoneal. 93 After traumatic brain injury, it counteracts the otherwise progressing course. 104 In rat spinal cord compression with tail paralysis, axonal and neuronal necrosis, demyelination, cyst formation, BPC 157 result in marked recovery and rescues tail function in both short-terms and long-terms. 142 After NSAIDs [54] [55] [56] [57] 61 or insulin overdose 143 or cuprizone (a neurotoxin that induces multiple sclerosis like lesion in rat model) 92 Finally, as a conclusive point, BPC 157 interacts with several molecular pathways as it was demonstrated by many other groups as well. [96] [97] [98] [99] [100] [101] The wide range of the implicated pathways and thereby the functions known to be mediated by those pathways may be certainly a consistent background for the wide range of the BPC 157 claimed in our elaboration of the cytoprotection concept application in therapy. In this, of particular importance may be the resolving evidence that BPC 157 counteracted tumor cachexia. Along with the counteracted increase of pro-inflammatory cytokines such as interleukin-6, tumor necrosis factor-α, looking at muscle metabolism relevant to cancer cachexia, BPC 157 counteracted muscle wasting, significantly corrected deranged muscle proliferation as well as myogenesis, the changes in the expression of transcription factor (FoxO3a), phospho-AKT (p-AKT), phospho mammalian target of rapamycin (p-mTOR), and phospho glycogen synthase kinase 3β (p-GSK-3β). 2 Of note, BPC 157 recovery muscle and muscle function occurs upon direct traumas (that would result in the severe injuries that would be hardly healed spontaneously). [69] [70] [71] [72] [73] Likewise, it occurs after vascular occlusion, 94 
CONCLUSIONS
As a general common point, the Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection [14] [15] [16] [17] [18] [19] much like the Selye's stress coping response, [22] [23] [24] [25] both receive an increasing popularity, but limited practical applicability when largely confronted with humbler but more precise ideas. Since the very beginning, Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection has been in the focus on the demonstration of the particular beneficial effect of the cytoprotectants, using prostaglandins as the prototype, but also other standard cytoprotectants. On that account, innate beneficial effect, Robert's stomach cytoprotection/adaptive cytoprotection/ organoprotection [14] [15] [16] [17] [18] [19] tolerates the lack of the full understanding of the involved mechanisms, specific cellular changes seldom identified, the surface epithelial cells not protected, electrophysiologic parameters (potential difference) instead macroscopic/ microscopic assessments. 148 Thus, if the strength of the particular beneficial effect is the most important proof of the concept with the prostaglandins and other standard cytoprotectants, we have to admit that Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection tolerates no recovery of the preexisting stomach lesions, providing only prophylactic effect. [14] [15] [16] [17] [18] [19] Also, there are very limited extension of the standard cytoprotectants effect from the stomach lesions to other organs lesions (liver, pancreas), 20, 21 thus a quite limited cytoprotective and organoprotective therapeutic potential. Finally, Robert's concept has a methodology issue. 53 It applies necrotizing agent (i.e., absolute alcohol) intragastrically, delivery goes directly through the inserted orogastric tube into the stomach (procedure that Robert [incorrectly] referred as oral application). [14] [15] [16] [17] [18] [19] Far from reality of the regular per-oral application, it means completely "unprepared stomach" to an unusual event. Contrarily, we recently demonstrated that the new initial target is the tongue, resulting in spontaneous reversal of strong alcohol-stomach lesions. 53 BPC 157 therapy functions also within the redirected complexity of Robert's stomach cytoprotection/ adaptive cytoprotection concept. 53 Likewise, the follow-up of the Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection [14] [15] [16] [17] [18] [19] much like the Selye's stress coping response, [22] [23] [24] [25] done by BPC 157, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] reveals that the extensive demonstration of the beneficial effects may have similar problems as original concepts with the less focused involved mechanisms. However, the achieved demonstration of the beneficial effects, and thereby stomach cytoprotection → organoprotection more reliable realization, involves the whole gastrointestinal tract, both prophylactic and therapeutic effect, including the pre-existing lesions in the most complex disturbances, such as the internal and external fistulas, or anastomosis complicated with severe colitis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] There is a particular effect on endothelium integrity as well. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Likewise, originally, BPC 157 effect was ascribed to its interaction and modulation of NO-system, while the interaction with prostaglandins, dopamine, and serotonin systems was also documented. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] BPC 157 also acts as a free radical scavenger, and normalizes NO-and MDA-levels in tissues, in ischemia and reperfusion. 101, 113, 114, [116] [117] [118] There are subsequent particular studies of other groups, 2,96-101 confirmation of the our original findings. [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] Pleiotropic effect involving distinctive receptors, VEGF receptor 2 (VEGFR2), growth hormone receptors, distinctive pathways, VEGFR2-AKT-eNOS (endothelial NOS), ERK½, focal adhesion kinase-paxillin, FoxO3a, p-AKT, p-mTOR and p-GSK-3β, distinctive loops, stimulation egr-1 gene and its corepressor gene naB2, counteraction of the increased pro-inflammatory and pro-cachectic cytokines, 2, [96] [97] [98] [99] [100] [101] would likely minimize the inherent lack of full understanding of the mechanisms which may be involved. But more important is the practical indicative evidence that even with the majority of studies on BPC 157 done on rodents given injection of the supplement, there are considerable number of the studies, particularly in gastrointestinal research, intragastric application or per-oral application in drinking water, correspondingly effective. 12, 41, 43, 48, 51, 54, 55, 58, 59, [61] [62] [63] [82] [83] [84] [85] 89, [91] [92] [93] 98, 114, 116, 117, [143] [144] [145] [146] [147] [149] [150] [151] [152] [153] [154] [155] In reality, in particular along with its safe profile, LD-1 not achieved, and no adverse effects in clinical trials, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] this evidence suggests easy practical clinical application (Fig. 1 Selye's concept of stress response against stress injury to reestablish disturbed homeostasis. [22] [23] [24] [25] 40 Thus, in practice, these findings may be relevant to resolving Robert's cytoprotection/adaptive cytoprotection/organoprotection, [14] [15] [16] [17] [18] [19] [20] [21] and consequently, Selye's stress coping response, [22] [23] [24] [25] 40 and practical applicability.
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